April 27, 2024

• 

[THE INVESTOR] Celltrion’s biosimilars will continue to sell briskly, said IBK Securities on Oct. 19, maintaining a “buy” recommendation and raising the target price to 225,000 won (US$198.85) from 145,000 won.

Considering Herzuma exports to Europe have been pushed back to next year and the inventory of Celltrion Healthcare, Celltrion’s earnings prospect for this year will be lower than estimated, but its mid-term growth potential remains unchanged, said analyst Park Si-hyeong.

Truxima is selling better than expected in Europe despite the launch of a rival product, and with the scheduled introduction of Truxima in the US in 2019, and Herzuma in Europe and the US, its revenue will remain strong, noted the analyst. 

Its rival Biocon’s biosimilar has been rejected by US authorities and Celltrion’s manufacturing capacity is being highlighted, said Park underlining the company’s unrivaled status. 

By Hwang You-mee (glamazon@heraldcorp.com)